BD’s Onclarity HPV Assay: What it means for the future of cervical cancer detection

In a recent study, under-screened patients were more likely to receive cervical cancer screening after receiving at-home high-risk human papillomavirus sampling kits.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

In a unanimous vote, norgestrel (Opill; HRA Pharma) has been backed by an FDA advisory panel as an over-the-counter birth control pill.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

In a recent study, female patients born by cesarean delivery were more likely to experience early-onset colorectal cancer.

In a recent study, histologic subtype accounted for 54.1% of the excess relative risk for Black patients compared to White patients with uterine cancer.